Physician profile
Sumedha Singh
NPI 1770077927
$1,897.64
in general payments reported to CMS, 2019-2025
16 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.88 · 2023: $294 · 2024: $433 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.43 | 2022-2025 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $288.08 | 2024-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $177.00 | 2024-2025 | Dupixent |
| Medtronic, INC. | $152.84 | 2023 | Barrx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.93 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Celltrion USA INC. | $146.46 | 2024-2025 | Vegzelma |
| Janssen Biotech, INC. | $118.30 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $114.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $106.28 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $68.29 | 2025 | |
| Lilly USA, LLC | $55.39 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $50.01 | 2025 | Zenpep |
| Ardelyx, INC. | $37.47 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $28.52 | 2024 | Voquezna |
| Genzyme Corporation | $19.07 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.16 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumedha Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.